Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors
/in Dendritic Cells, International Publications /von 2010-04-20 / Semin. Immunol. 2010 Jun;22(3):173-82Antigen-specific polyclonal cytotoxic T lymphocytes induced by fusions of dendritic cells and tumor cells
/in Dendritic Cells, International Publications /von 2010-04-07 / J. Biomed. Biotechnol. 2010;2010:752381Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours
/in Brain Tumors in Children, Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2010-04-01 / Pediatr Blood Cancer 2010 Apr;54(4):519-25Dendritic cell vaccines to combat glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2010-04-01 / Expert Rev Neurother 2010 Apr;10(4):483-6Differential effects of Paclitaxel on dendritic cell function
/in Dendritic Cells, International Publications /von 2010-03-19 / BMC Immunol. 2010 Mar;11:14Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells
/in Dendritic Cells, International Publications /von 2010-03-18 / Ann. Hematol. 2010 Aug;89(8):795-801Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2010-03-12 / Lung Cancer 2010 Nov;70(2):188-94Building on dendritic cell subsets to improve cancer vaccines
/in Dendritic Cells, International Publications /von 2010-03-11 / Curr. Opin. Immunol. 2010 Apr;22(2):258-63Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy
/in Dendritic Cells, International Publications /von 2010-03-05 / Cancer Immunol. Immunother. 2010 Oct;59(10):1573-82
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution